- Home
- ALZN vs QLGN Comparison
ALZN vs QLGN Comparison
Compare ALZN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- QLGN
- Stock Information
- Founded
- ALZN 2016
- QLGN 1996
- Country
- ALZN United States
- QLGN United States
- Employees
- ALZN N/A
- QLGN N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- QLGN Health Care
- Exchange
- ALZN Nasdaq
- QLGN Nasdaq
- Market Cap
- ALZN 2.3M
- QLGN 2.3M
- IPO Year
- ALZN 2021
- QLGN N/A
- Fundamental
- Price
- ALZN $3.20
- QLGN $3.38
- Analyst Decision
- ALZN Strong Buy
- QLGN
- Analyst Count
- ALZN 1
- QLGN 0
- Target Price
- ALZN $180.00
- QLGN N/A
- AVG Volume (30 Days)
- ALZN 429.8K
- QLGN 15.1K
- Earning Date
- ALZN 09-10-2025
- QLGN 08-13-2025
- Dividend Yield
- ALZN N/A
- QLGN N/A
- EPS Growth
- ALZN N/A
- QLGN N/A
- EPS
- ALZN N/A
- QLGN N/A
- Revenue
- ALZN N/A
- QLGN N/A
- Revenue This Year
- ALZN $322.64
- QLGN N/A
- Revenue Next Year
- ALZN N/A
- QLGN N/A
- P/E Ratio
- ALZN N/A
- QLGN N/A
- Revenue Growth
- ALZN N/A
- QLGN N/A
- 52 Week Low
- ALZN $2.75
- QLGN $2.85
- 52 Week High
- ALZN $135.54
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- ALZN 47.56
- QLGN 44.06
- Support Level
- ALZN $2.81
- QLGN $3.15
- Resistance Level
- ALZN $3.05
- QLGN $3.99
- Average True Range (ATR)
- ALZN 0.17
- QLGN 0.25
- MACD
- ALZN 0.09
- QLGN 0.00
- Stochastic Oscillator
- ALZN 75.01
- QLGN 27.94
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.